Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

47.24USD
24 May 2017
Change (% chg)

$-1.32 (-2.72%)
Prev Close
$48.56
Open
$48.77
Day's High
$49.20
Day's Low
$46.57
Volume
597,231
Avg. Vol
584,944
52-wk High
$67.74
52-wk Low
$35.84

AGIO.O

Chart for AGIO.O

About

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $2,340.83
Shares Outstanding(Mil.): 48.20
Dividend: --
Yield (%): --

Financials

  AGIO.O Industry Sector
P/E (TTM): -- 141.11 17.36
EPS (TTM): -6.01 -- --
ROI: -58.46 2.25 -5.72
ROE: -75.48 0.17 -5.10

BRIEF-Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals

* Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals for next-generation sequencing oncology companion diagnostic in cholangiocarcinoma

May 18 2017

BRIEF-Agios Pharmaceuticals to present updated clinical data from PKR activator AG-348

* Agios Pharmaceuticals Inc says to present updated clinical data from PKR activator AG-348 at EHA Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Agios Pharmaceuticals Inc Q1 net loss was $66.2 million

* Agios Pharmaceuticals Inc - net loss for quarter ended March 31, 2017 was $66.2 million, compared to a net loss of $23.2 million for quarter ended March 31, 2016

May 04 2017

BRIEF-Agios announces closing of over-allotment option in public offering

* Agios announces closing of over-allotment option in public offering

Apr 28 2017

BRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target

* Agios and aurigene enter into exclusive license agreement for novel small molecules for cancer metabolism target

Apr 27 2017

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Mar 13 2017

BRIEF-Agios says cash, marketable securities were $573.6 mln as of Dec. 31

* Agios reports fourth quarter and full year 2016 financial results and highlights key 2017 milestones

Feb 16 2017

BRIEF-Agios pharmaceuticals AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

* AG-120 NDA submission for IDH1M R/R AML planned by year end 2017

Jan 09 2017

More From Around the Web

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.05 -0.09
Novartis AG (NOVN.S) CHF79.10 +0.05
Roche Holding Ltd. (ROG.S) CHF267.20 -0.70
Roche Holding Ltd. (RO.S) CHF267.50 +0.25
Sanofi SA (SASY.PA) €87.60 --
AstraZeneca plc (AZN.L) 5,185.00 --
GlaxoSmithKline plc (GSK.L) 1,633.50 --
Eli Lilly and Co (LLY.N) $77.96 -0.03
Shire PLC (SHP.L) 4,778.50 --
Shire PLC (3159084.L) -- --

Earnings vs. Estimates